Cancer Trials Should Show Minimum 20% Overall Survival Benefit, ASCO Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
American Society of Clinical Oncology draft recommendations provide benchmarks for Phase III oncology drug trials, including a minimum 20% improvement in overall survival, with a higher bar for certain diseases.